This article is more than 5 years old. Information may no longer be current.
Research at ASH highlights progress, unmet needs in multiple myeloma
Click Here to Manage Email Alerts
Multiple myeloma was a critical area of focus at the 60th ASH Annual Meeting and Exposition, held from Dec. 1-4, 2018.
Results of an international phase 3 trial showed the addition of the monoclonal antibody daratumumab (Darzalex, Janssen Oncology) to lenalidomide (Revlimid, Celgene) and dexamethasone nearly halved the risk for disease progression or death among transplant-ineligible, newly diagnosed patients. Additional trials further demonstrated the promise of novel immunotherapy agents and explored optional treatment regimens for patients.
Despite progress, researchers also described a need to improve patient care. Significant racial disparities were observed in the receipt of supportive care services for bone health and infection prevention. In addition, a population-based study revealed that only about half of Medicare beneficiaries with multiple myeloma received treatment with bone-modifying agents, even though these agents are recommended by the International Myeloma Working Group and ASCO for all patients initiating multiple myeloma therapy.
This supplement, brought to you by the publishers of HemOnc Today, highlights the most up-to-date research on multiple myeloma presented at ASH. Perspectives from leaders in the field offer additional insight into the impact these findings may have in practice.
Click here to view the interactive PDF and visit the ASH Annual Meeting and Exposition Resource Center for news in other research in malignant and non-malignant hematology presented at the conference.
